title: Self-adjuvanting glycopeptide conjugate vaccine against disseminated candidiasis.
abstract: Our research on pathogenesis of disseminated candidiasis led to the discovery that antibodies specific for Candida albicans cell surface β-1, 2-mannotriose [β-(Man)(3)] protect mice. A 14 mer peptide Fba, which derived from the N-terminal portion of the C. albicans cytosolic/cell surface protein fructose-bisphosphate aldolase, was used as the glycan carrier and resulted in a novel synthetic glycopeptide vaccine β-(Man)(3)-Fba. By a dendritic cell-based immunization approach, this conjugate induced protective antibody responses against both the glycan and peptide parts of the vaccine. In this report, we modified the β-(Man)(3)-Fba conjugate by coupling it to tetanus toxoid (TT) in order to improve immunogenicity and allow for use of an adjuvant suitable for human use. By new immunization procedures entirely compatible with human use, the modified β-(Man)(3)-Fba-TT was administered either alone or as a mixture made with alum or monophosphoryl lipid A (MPL) adjuvants and given to mice by a subcutaneous (s.c.) route. Mice vaccinated with or, surprisingly, without adjuvant responded well by making robust antibody responses. The immunized groups showed a high degree of protection against a lethal challenge with C. albicans as evidenced by increased survival times and reduced kidney fungal burden as compared to control groups that received only adjuvant or DPBS buffer prior to challenge. To confirm that induced antibodies were protective, sera from mice immunized against the β-(Man)(3)-Fba-TT conjugate transferred protection against disseminated candidiasis to naïve mice, whereas C. albicans-absorbed immune sera did not. Similar antibody responses and protection induced by the β-(Man)(3)-Fba-TT vaccine was observed in inbred BALB/c and outbred Swiss Webster mice. We conclude that addition of TT to the glycopeptide conjugate results in a self-adjuvanting vaccine that promotes robust antibody responses without the need for additional adjuvant, which is novel and represents a major step forward in vaccine design against disseminated candidiasis.
authors.affiliation: Department of Pediatrics, Louisiana State University Health Sciences Center and Research Institute for Children, Children's Hospital, New Orleans, Louisiana, United States of America. hxin@chnola-research.org
authors.forename: Hong
authors.initials: H
authors.lastname: Xin
authors.forename: Jonathan
authors.initials: J
authors.lastname: Cartmell
authors.forename: Justin J
authors.initials: JJ
authors.lastname: Bailey
authors.forename: Sebastian
authors.initials: S
authors.lastname: Dziadek
authors.forename: David R
authors.initials: DR
authors.lastname: Bundle
authors.forename: Jim E
authors.initials: JE
authors.lastname: Cutler
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D000908:Antibodies, Fungal / Q000276:immunology; D000917:Antibody Formation; D002176:Candida albicans / Q000276:immunology; D002177:Candidiasis / Q000276:immunology / Q000517:prevention & control*; D005657:Fungal Vaccines / Q000276:immunology; D006020:Glycopeptides / Q000737:chemistry / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D013745:Tetanus Toxoid / Q000737:chemistry / Q000276:immunology; D018074:Vaccines, Conjugate / Q000737:chemistry / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000908:Antibodies, Fungal; D005657:Fungal Vaccines; D006020:Glycopeptides; D013745:Tetanus Toxoid; D018074:Vaccines, Conjugate